(12) International Application Status Report

Received at International Bureau: 17 September 2018 (17.09.2018)

Information valid as of: 12 February 2019 (12.02.2019)

Report generated on: 20 September 2019 (20.09.2019)

(10) Publication number: (43) Publication date: (26) Publication language:
WO 2019/04659407 March 2019 (07.03.2019) English (EN)

(21) Application number: (22) Filing date: (25) Filing language:
PCT/US2018/04887930 August 2018 (30.08.2018) English (EN)

(31) Priority number(s): (32) Priority date(s): (33) Priority status:
62/552,952 (US)31 August 2017 (31.08.2017) Priority document received (in compliance with PCT Rule 17.1)

(51) International Patent Classification:
A61K 45/00 (2006.01); A61K 31/00 (2006.01); C07K 14/16 (2006.01)

(71) Applicant(s):
THE REGENTS OF THE UNIVERSITY OF CALIFORNIA [US/US]; 1111 Franklin Street Twelfth Floor Oakland, California 94607-5200 (US) (for all designated states)

(72) Inventor(s):
JIANG, Guochun; 1850 Research Park Drive Suite 300 Davis, California 95618-6153 (US)
DANDEKAR, Satya; 1850 Research Park Drive Suite 300 Davis, California 95618-6153 (US)

(74) Agent(s):
GIDDINGS, Barton W.; Stoel Rives LLP 201 South Main Suite 1100 Salt Lake City, Utah 84111 (US)

(54) Title (EN): METHODS OF REACTIVATING LATENT HUMAN IMMUNODEFICIENCY VIRUS AND RELATED COMPOSITIONS
(54) Title (FR): MÉTHODES DE RÉACTIVATION DU VIRUS DE L'IMMUNODÉFICIENCE HUMAINE LATENT ET COMPOSITIONS ASSOCIÉES

(57) Abstract:
(EN): Methods of reactivating latent human immunodeficiency virus (HIV) in one or more cells of a patient infected with HIV are provided. Methods of treating HIV infection and acquired immune deficiency syndrome (HIV/AIDS) in a patient are also provided. The methods can include administering a crotonylation-inducing agent to the patient. The methods can also include administering a crotonylation-inducing agent and one or more additional latency reversal agents (LRAs) to the patient. Pharmaceutical compositions including a crotonylation-inducing agent or pharmaceutical compositions including a crotonylation-inducing agent and one or more additional LRAs are also provided.
(FR): L'invention concerne des méthodes de réactivation du virus de l'immunodéficience humaine (VIH) latent dans une ou plusieurs cellules d'un patient infecté par le VIH. L'invention concerne également des méthodes de traitement d'une infection à VIH et du syndrome d'immunodéficience acquise (VIH/SIDA) chez un patient. Les méthodes peuvent comprendre l'administration au patient d'un agent induisant la crotonylation. Les méthodes peuvent également comprendre l'administration au patient d'un agent induisant la crotonylation et d'un ou de plusieurs autres agents de réversion de la latence (LRA). L'invention concerne également des compositions pharmaceutiques comprenant un agent induisant la crotonylation ou des compositions pharmaceutiques comprenant un agent induisant la crotonylation et un ou plusieurs autres LRAs.

International search report:
Received at International Bureau: 14 December 2018 (14.12.2018) [US]

International Report on Patentability (IPRP) Chapter II of the PCT:
Not available

(81) Designated States:
AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW
European Patent Office (EPO) : AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR
African Intellectual Property Organization (OAPI) : BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG
African Regional Intellectual Property Organization (ARIPO) : BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW
Eurasian Patent Organization (EAPO) : AM, AZ, BY, KG, KZ, RU, TJ, TM

Declarations:
Declaration made as applicant's entitlement, as at the international filing date, to apply for and be granted a patent (Rules 4.17(ii) and 51bis.1(a)(ii)), in a case where the declaration under Rule 4.17(iv) is not appropriate